- $423.23m
- $146.11m
- $4.66m
Notice of Results
PRTC Publishes Phase 2b Deupirfenidone IPF Results
PRTC's Seaport: Positive Topline Ph1 for GlyphAgo
PRTC’s Seaport: GlyphAllo Paper Published
PDMR Notification RSU Vesting
PRTC to Present at Leerink Healthcare Conference
Brief: Puretech's Deupirfenidone Receives Orphan Drug Status from US FDA, EU for Pulmonary Fibrosis
PRTC's Deupirfenidone Granted FDA & EU ODD for IPF
PureTech to Present at the JP Morgan Conference
PureTech Appoints Robert Lyne as CEO
Holding(s) in Company
UK's PureTech climbs after successful US FDA meeting
PRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
Brief: PureTech Health Says LYT-200 Shows Favorable Tolerability And Efficacy In Phase 1b Trial
PRTC's Gallop: Positive Initial Topline AML Data
PureTech Health PLC Citigroup Inc - Holding(s) in Company
PureTech Health PLC Citigroup Inc - Holding(s) in Company
Prtc: New Lyt: 200 AML Data + Update at ASH
PRTC: New IPF Data Show Benefit in Older Patients